SCHEMBL189154

SCHEMBL189154

CN1CCC(C(O)c2ccc(N)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.46
HTR2C P28335 3/20 0.46
HTR7 P34969 2/20 0.46
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
KDM4E B2RXH2 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 1/20 0.44
HRH3 Q9Y5N1 2/20 0.42
HRH4 Q9H3N8 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
ADRA2C P18825 1/20 0.42
GFER P55789 1/20 0.42
KMT2A Q03164 1/20 0.42
PTK2B Q14289 1/20 0.42
ESR2 Q92731 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10112214 0.83 CCR5 (0.48) HTR2AHTR2CHTR7CARM1PRMT6
SCHEMBL3391983 0.83 HRH3 (0.55) HTR2AHTR2CHTR7CARM1PRMT6
SCHEMBL3394400 0.83 HTR2A (0.64) HTR2AHTR2CHTR7CARM1PRMT6
SCHEMBL3392214 0.82 CARM1 (0.63) HTR2AHTR2CCARM1PRMT6KDM4E
SCHEMBL188039 0.79 CARM1 (0.46) HTR2AHTR2CHTR7CARM1PRMT6
SCHEMBL23962815 0.78 HTR2A (0.41) HTR2AHTR2CHTR7CARM1PRMT6
SCHEMBL6213818 0.78 LMNA (0.41) HTR2AHTR2CKDM4ECYP2D6HRH3
SCHEMBL9328992 0.77 CYP2D6 (0.51) HTR2AHTR2CCARM1PRMT6KDM4E
SCHEMBL13175798 0.77 KMT2A (0.40) HTR2AHTR2CKDM4EALDH1A1GAA
SCHEMBL9179569 0.75 HTR2A (0.82) HTR2AHTR2CHTR7CARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK HTR2A 4687/4885HTR2C 3786/4885HTR7 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.